The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Time-limited venetoclax-rituximab in R/R CLL patients previously exposed to BTKi’s
In this video, Thomas Lew, MBBS(Hons), Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia, discusses a study which aimed to assess the efficacy of a time-limited venetoclax-rituximab regimen in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) previously exposed to covalent BTK inhibitors (BTKi’s). Although overall response rate and complete remission rate were high, with a median progression-free survival of 26 months, treatment-free remissions were rare, which means feasibility of time-limited therapies in this context is unclear. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
